Cited 7 times in
Evolution of liver fibrosis and steatosis markers in patients with type 2 diabetes after metformin treatment for 2 years
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Hye Won | - |
dc.contributor.author | Lee, Jae Seung | - |
dc.contributor.author | Kim, Beom Kyung | - |
dc.contributor.author | Park, Jun Yong | - |
dc.contributor.author | Kim, Do Young | - |
dc.contributor.author | Ahn, Sang Hoon | - |
dc.contributor.author | Kim, Seung Up | - |
dc.date.accessioned | 2021-03-31T01:42:24Z | - |
dc.date.available | 2021-03-31T01:42:24Z | - |
dc.date.created | 2021-02-22 | - |
dc.date.issued | 2021-01 | - |
dc.identifier.issn | 1056-8727 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/181848 | - |
dc.description.abstract | Background/aims: Type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD) share pathophysiological mechanism. Metformin is a widely used first-line anti-diabetic drug. We investigated the evolution of liver fibrosis and steatosis during 2-year use of metformin in patients with T2DM. Methods: Between 2006 and August 2010, patients newly diagnosed with T2DM who received metformin as the first-line treatment were recruited. Fibrosis-4 index (FIB-4) > 2.67 and hepatic steatosis index (HSI) > 36.0 was used to define advanced liver fibrosis and fatty liver, respectively. Results: A total of 1292 (mean age 60.8 years, 57% men and 43% women) patients were recruited. The mean FIB-4 and HSI scores were 1.38 and 27.3, respectively. At enrollment, 83 (6.4%) patients had advanced liver fibrosis and 429 (33.2%) had fatty liver. After 2 years of metformin treatment, the mean FIB-4 score increased from 1.38 to 1.51 (p < 0.001), whereas the mean HSI score decreased from 27.3 to 26.5 (p < 0.001). During follow-up, advanced liver fibrosis additionally developed in 52/1209 (4.3%) patients, whereas 48/83 (57.8%) experienced fibrosis regression. Older age (odds ratio [OR] = 1.007), lower platelet count (OR = 0.993), and lower serum albumin (OR = 0.325) were independently associated with the increased risk of advanced liver fibrosis development after 2-years of metformin treatment. Conclusion: In our cohort of patients with metformin treatment, a small proportion of patients developed liver fibrosis and steatosis after 2 years. Optimized follow-up strategy is required according to different risk of liver fibrosis progression in patients with T2DM. (C) 2020 Elsevier Inc. All rights reserved. | - |
dc.language | 영어 | - |
dc.publisher | ELSEVIER SCIENCE INC | - |
dc.relation.isPartOf | JOURNAL OF DIABETES AND ITS COMPLICATIONS | - |
dc.title | Evolution of liver fibrosis and steatosis markers in patients with type 2 diabetes after metformin treatment for 2 years | - |
dc.type | Article | - |
dc.contributor.googleauthor | Lee, Hye Won | - |
dc.contributor.googleauthor | Lee, Jae Seung | - |
dc.contributor.googleauthor | Kim, Beom Kyung | - |
dc.contributor.googleauthor | Park, Jun Yong | - |
dc.contributor.googleauthor | Kim, Do Young | - |
dc.contributor.googleauthor | Ahn, Sang Hoon | - |
dc.contributor.googleauthor | Kim, Seung Up | - |
dc.identifier.doi | 10.1016/j.jdiacomp.2020.107747 | - |
dc.relation.journalcode | J01376 | - |
dc.identifier.eissn | 1873-460X | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S1056872720305286 | - |
dc.subject.keyword | Diabetes | - |
dc.subject.keyword | Metformin | - |
dc.subject.keyword | Liver fibrosis | - |
dc.subject.keyword | Liver steatosis | - |
dc.contributor.affiliatedAuthor | Lee, Hye Won | - |
dc.contributor.affiliatedAuthor | Lee, Jae Seung | - |
dc.contributor.affiliatedAuthor | Kim, Beom Kyung | - |
dc.contributor.affiliatedAuthor | Park, Jun Yong | - |
dc.contributor.affiliatedAuthor | Kim, Do Young | - |
dc.contributor.affiliatedAuthor | Ahn, Sang Hoon | - |
dc.contributor.affiliatedAuthor | Kim, Seung Up | - |
dc.identifier.scopusid | 2-s2.0-85094562609 | - |
dc.identifier.wosid | 000600377000016 | - |
dc.citation.title | JOURNAL OF DIABETES AND ITS COMPLICATIONS | - |
dc.citation.volume | 35 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 107747 | - |
dc.identifier.bibliographicCitation | JOURNAL OF DIABETES AND ITS COMPLICATIONS, Vol.35(1) : 107747, 2021-01 | - |
dc.identifier.rimsid | 67623 | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordAuthor | Diabetes | - |
dc.subject.keywordAuthor | Metformin | - |
dc.subject.keywordAuthor | Liver fibrosis | - |
dc.subject.keywordAuthor | Liver steatosis | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | NAFLD | - |
dc.subject.keywordPlus | PREVALENCE | - |
dc.subject.keywordPlus | TARGETS | - |
dc.subject.keywordPlus | IMPACT | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalWebOfScienceCategory | Endocrinology & Metabolism | - |
dc.relation.journalResearchArea | Endocrinology & Metabolism | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.